Article Access statistics

Viewed: 779

Emailed: 0

PDF Downloaded: 197

Indian Journal of Pharmacy and Pharmacology

Evaluation of Efficacy of Nevirapine Regimen versus Efavirenz Regimen

Full Text PDF Share on Facebook Share on Twitter

Author Details : Usha Adiga, Sachidanada Adiga, BN Malawadi

Volume : 3, Issue : 2, Year : 2016

Article Page : 84-87

Suggest article by email


Introduction: CD4 count can be used as marker to assess the effectiveness of antiretro viral treatment (ART), mortality and survival rates in HIV patients. It is an important guide to treatment as it reflects drug resistance, treatment failure and need to switch over to different regimen. Objective of the study was to assess the effectiveness of two regimens, Nevirapine (NVP) versus Efavirenz (EFV), both in combination with Zidovudine (AZT) and Lamivudine (3TC) in HIV patients. 
Methods: A retrospective observational study on 48 adult HIV patients, receiving AZT+3TC+NPV (ZLN) (group I) and 28 patients on AZT+3TC+EFV (ZLE) (group II) was carried out. Demographic profile, medication prescribed, baseline CD4 cell counts, serially monitored CD4 count values for 2 years  and Hb% were recorded from patient's medical record.Basal and 2 yr CD4 counts were compared using suitable statistical tests.
Results: A very highly significant (p=0.0001) increment in CD4 count was observed in both the groups after treatment. Mean CD4 count of 2 years was significantly high (p=0.038) in patients on EFV regimen as compared to those on NVP. 
Conclusion: We conclude that ART regimen containing EFV is superior to NVP. However further studies need to be done in this area, by taking adherence to treatment, concomitant infections, ADRs in to consideration.

Key words
:  CD4 Count, Efavirenz, Nevirapine

How to cite : Adiga U, Adiga S, Malawadi B, Evaluation of Efficacy of Nevirapine Regimen versus Efavirenz Regimen. Indian J Pharm Pharmacol 2016;3(2):84-87

Copyright © 2016 by author(s) and Indian J Pharm Pharmacol. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC-BY-NC 4.0) (